Companies › Zenith Epigenetics
1 active drug program in 3 registered trials: 3 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZEN003694 HDAC inhibitor | – | Phase 2 | Metastatic Castration-Resistant Prostate Cancer; Squamous Cell Lung Cancer; Ovarian Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04986423 | ZEN003694 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Oncology | Dec 2026 |
| NCT05607108 | ZEN003694 | Phase 2 | Squamous Cell Lung Cancer | Oncology | Nov 2027 |
| NCT05071937 | ZEN003694 | Phase 2 | Ovarian Cancer | Oncology | Nov 2033 |
No annotated target.
–
Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.